Mestinon

Myasthenic Syndromes, Congenital, Constipation, Gas Poisoning + 6 more
Treatment
20 Active Studies for Mestinon

What is Mestinon

PyridostigmineThe Generic name of this drug
Treatment SummaryMyasthenia gravis is a condition that causes the muscles to weaken and tire easily. Pyridostigmine is a medication used to treat myasthenia gravis. It works by blocking the breakdown of acetylcholine, a chemical in the body that helps muscles move. Pyridostigmine was first approved by the FDA in 1955 and is available in tablets, syrups, and injections. It is also used to reverse nerve blocks, ease symptoms of congenital myasthenic syndromes, and protect against certain nerve agents.
Mestinonis the brand name
image of different drug pills on a surface
Mestinon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mestinon
Pyridostigmine
1955
38

Effectiveness

How Mestinon Affects PatientsPyridostigmine bromide is taken orally and works by blocking an enzyme (cholinesterase) that breaks down certain chemicals in the body. It is similar to another drug (neostigmine) but has fewer side effects and lasts longer. If too much of the drug is taken, it can cause a cholinergic crisis, which shows symptoms similar to a myasthenic crisis. In this case, atropine is usually given to counteract the side effects.
How Mestinon works in the bodyMyasthenia gravis is an autoimmune condition that affects the way nerve signals reach muscles. It is caused by antibodies that bind to molecules involved in these signals, like the acetylcholine receptor. This reduces the ability of the nerve to communicate with the muscles, causing weakness and fatigue. Pyridostigmine is a drug used to treat myasthenia gravis. It works by blocking an enzyme called acetylcholinesterase, which breaks down the molecules involved in nerve-muscle communication. This increases the amount of the molecules available, resulting in improved nerve-muscle communication and improved

When to interrupt dosage

The suggested quantity of Mestinon is contingent upon the diagnosed circumstance, including non-depolarizing neuromuscular blocking agents, Neuromuscular Blockade and Gas Poisoning. The amount of dosage is contingent upon the method of delivery (e.g. Oral or Solution - Oral) detailed in the table below.
Condition
Dosage
Administration
Gas Poisoning
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Gas Poisoning
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Hypotension, Orthostatic
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
non-depolarizing neuromuscular blocking agents
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Myasthenic Syndromes, Congenital
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Constipation
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Neuromuscular Blockade
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Myasthenia Gravis
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral
Postpoliomyelitis Syndrome
, 180.0 mg, 60.0 mg, 5.0 mg/mL, 60.0 mg/mL, 30.0 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous; Parenteral, Liquid, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup - Oral, Solution, Solution - Oral

Warnings

Mestinon has three contraindications and must not be combined with the conditions listed in the ensuing table.Mestinon Contraindications
Condition
Risk Level
Notes
Mechanical Intestinal Obstruction
Do Not Combine
mechanical urinary obstructions
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Pyridostigmine may interact with Pulse Frequency
There are 20 known major drug interactions with Mestinon.
Common Mestinon Drug Interactions
Drug Name
Risk Level
Description
Acetylcholine
Minor
The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Acetylcholine.
Agmatine
Minor
The therapeutic efficacy of Agmatine can be decreased when used in combination with Pyridostigmine.
Alcuronium
Minor
The therapeutic efficacy of Alcuronium can be decreased when used in combination with Pyridostigmine.
Amantadine
Minor
The therapeutic efficacy of Amantadine can be decreased when used in combination with Pyridostigmine.
Amitriptyline
Minor
The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Pyridostigmine.
Mestinon Toxicity & Overdose RiskNot much is known about the toxic effects of pyridostigmine. Overdosing may lead to a range of adverse effects, including slow heartbeat, excessive mucus in the lungs, and a cholinergic crisis. To treat an overdose, doctors may suggest supportive treatments.
image of a doctor in a lab doing drug, clinical research

Mestinon Novel Uses: Which Conditions Have a Clinical Trial Featuring Mestinon?

59 active clinical trials are currently assessing the potential of Mestinon to alleviate Myasthenic Syndromes, Congenital Disorders, Chronic Constipation and Gas Poisoning.
Condition
Clinical Trials
Trial Phases
Myasthenia Gravis
15 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Constipation
18 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1
Hypotension, Orthostatic
0 Actively Recruiting
Neuromuscular Blockade
3 Actively Recruiting
Not Applicable, Phase 4
Myasthenic Syndromes, Congenital
1 Actively Recruiting
Phase 1
Gas Poisoning
0 Actively Recruiting
non-depolarizing neuromuscular blocking agents
0 Actively Recruiting
Gas Poisoning
0 Actively Recruiting
Postpoliomyelitis Syndrome
0 Actively Recruiting

Mestinon Reviews: What are patients saying about Mestinon?

5Patient Review
7/24/2015
Mestinon for Myasthenia Gravis
The only problem I have is that mestinon has given me an irregular heart rhythm, which I read is a side effect.
5Patient Review
1/9/2017
Mestinon for Myasthenia Gravis
I was diagnosed with myasthenia gravis in 2002. I started taking this medication in liquid form, but as I've gotten older I only need to take it three times a day. It's been effective overall, though I have experienced some leg cramps and muscle spasms as side effects. Another downside is that it doesn't seem to help much with drooping eyelids.
5Patient Review
9/28/2015
Mestinon for Myasthenia Gravis
I've been taking this medication for almost 30 years now. When I first started, the muscle spasms were really bad. But after a few months, my body got used to it and the fatigue eased up. I take 60mg in the morning with food, 2-3 PM and before I go to bed.
5Patient Review
3/24/2017
Mestinon for Myasthenia Gravis
I've been taking this for almost a decade now, and it's still helping me. Within hours of taking the first dose, I saw marked improvement. Recently had to switch to liquid form due to insurance issues, which I'm not thrilled about; however, it's still better than nothing.
4.7Patient Review
6/1/2018
Mestinon for Myasthenia Gravis
I had been dealing with undiagnosed myasthenia gravis for five months before finally being admitted to the hospital. The team of neurologists there quickly diagnosed and treated me; and within hours, all of my symptoms and problems were gone. This drug quite literally worked miracles for me.
4Patient Review
8/31/2013
Mestinon for Myasthenia Gravis
4Patient Review
9/22/2013
Mestinon for Myasthenia Gravis
3.7Patient Review
5/5/2017
Mestinon for Myasthenia Gravis
I started using Mestinon by Zydus today, but had to up the dosage because I didn't feel as though it was working effectively. Previously, I used Mestinon by Impax with no issues.
3Patient Review
7/23/2014
Mestinon for Myasthenia Gravis
I've been experiencing some pretty severe muscle cramping and stomach pains, as well as diarrhea. I'm only a week in so I'm hoping the side effects will lessen with time. They're definitely scary though; I've had issues with double vision, swallowing, and choking on my saliva. So far the medication hasn't really helped with those symptoms much.
2.3Patient Review
2/7/2017
Mestinon for Myasthenia Gravis
I've been taking this medication for over 17 years now. Unfortunately, it's caused some serious dental problems and I don't know where to turn next.
2Patient Review
10/1/2014
Mestinon for Myasthenia Gravis
I unfortunately have had some bad luck with this medication. I now experience neck pain quite severely and often.
1Patient Review
7/3/2014
Mestinon for Myasthenia Gravis
The recommended dosage is every five hours, so I started at 5pm. By 6:30, I had awful stomach cramps and diarrhea. The second dose was at 10pm; I woke up several times throughout the night with more diarrhea and cramps. At 7am, I took the third dose, but by 8:30 my tongue was swollen and I could barely speak - turns out that this was an allergic reaction to the medication! So not only did this treatment NOT work, it made things worse than the disease itself.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mestinon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of the medication Mestinon?

"You may experience nausea, vomiting, diarrhea, abdominal cramps, increased saliva/sweating, runny nose, decreased pupil size, or increased urination. If you experience any of these effects for an extended period of time, or if they worsen, tell your doctor or pharmacist."

Answered by AI

What are the benefits of Mestinon?

"Acetylcholine is needed for the proper functioning of your nerve cells and muscles.

MESTINON is a treatment for myasthenia gravis, which is a condition that results in muscle weakness and fatigue, especially with repeated use. MESTINON is a cholinergic antimyasthenic, which is a group of medicines that work by preventing the breakdown of a chemical called acetylcholine. Acetylcholine is necessary for the proper functioning of your nerve cells and muscles."

Answered by AI

Who should not take Mestinon?

"You shouldn't take Mestinon if you're allergic to it or if you have a bladder or bowel obstruction. Make sure it's safe for you to take Mestinon by telling your doctor if you have asthma or kidney disease."

Answered by AI

What is the drug Mestinon used for?

"MESTINON is a medication used to treat myasthenia gravis, a long term condition that causes weakened and easily tired muscles, especially after repeated use. It is also used to treat postoperative urinary retention, a condition where an individual is unable to urinate after surgery."

Answered by AI

Clinical Trials for Mestinon

Image of Center for Nutraceutical and Dietary Supplement Research in Memphis, United States.

Inno Cleanse for Abdominal Bloating

18+
All Sexes
Memphis, TN
The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months. Despite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness. Therefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.
Recruiting
Paid Trial
Center for Nutraceutical and Dietary Supplement ResearchRichard Bloomer, PhD
Have you considered Mestinon clinical trials? We made a collection of clinical trials featuring Mestinon, we think they might fit your search criteria.Go to Trials
Image of Banner - University Medical Center South in Tucson, United States.

Dexmedetomidine + Dexamethasone for Postoperative Pain

18 - 75
All Sexes
Tucson, AZ
The goal of this clinical study is to improve upon the standard practice of utilizing nerve blocks to enhance the satisfaction of patients undergoing shoulder, or foot and ankle surgery regarding their quality of pain control, the duration of their nerve blocks, as well as the avoidance of opioid medications and subsequently their undesirable side effects. The researchers hypothesize that dexmedetomidine and dexamethasone (Dex-Dex) will work synergistically as adjuncts in a low, non-weight based formula. This would allow the investigators to improve patient satisfaction by providing them with a superior means of pain control that is longer in duration with a decreased probability of unwanted side effects. The proposed clinical study will be a prospective, randomized control trial.
Phase 1 & 2
Waitlist Available
Banner - University Medical Center SouthRonald Tang, MD
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada
The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).
Phase 2 & 3
Waitlist Available
Hamilton Health SciencesElyanne Ratcliffe, MD
Have you considered Mestinon clinical trials? We made a collection of clinical trials featuring Mestinon, we think they might fit your search criteria.Go to Trials
Image of University of Alberta in Edmonton, Canada.

Pelvic Health Rehabilitation for Breast and Gynecologic Cancer

18+
Female
Edmonton, Canada
The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.
Recruiting
Has No Placebo
University of Alberta (+1 Sites)
Have you considered Mestinon clinical trials? We made a collection of clinical trials featuring Mestinon, we think they might fit your search criteria.Go to Trials